Orphan Medical Xyrem
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA extends its NDA review goal for the narcolepsy therapy sodium oxybate oral solution by 90 days, to early July, to review recently submitted data requested by the agency. FDA's Peripheral and Central Nervous System Advisory Committee is expected to schedule a June review of the dru